8-K 1 rel8k2q.txt FORM 8-K DATED AUGUST 13, 2004 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2004 HEMACARE CORPORATION (Exact Name of Registrant as Specified in its Charter) CALIFORNIA (State or other jurisdiction of incorporation) 000-15223 95-3280412 (Commission File No.) (IRS Employer Identification No.) 21101 Oxnard Street Woodland Hills, CA 91367 (Address of principal executive offices and Zip Code) Registrant's telephone number, including area code: (818) 226-1968 ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits Exhibit Number Description -------------- ----------------------------------------------- 99.1 Press Release issued by HemaCare, dated August 13, 2004 99.2 Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO,at a conference call conducted by HemaCare Corporation on August 13, 2004 ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 13, 2004, HemaCare Corporation issued a press release announcing financial results for the second quarter of 2004. A copy is attached as Exhibit 99.1 to this report and is incorporated herein by reference. On August 13, 2004, HemaCare Corporation held an investor conference call discussing the financial results for the second quarter of 2004. A transcript of the presentations given by Ms. Judi Irving, CEO, and Robert S. Chilton, CFO, in the call is attached to this report as Exhibit 99.2 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibits, will not be treated as "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2004 HEMACARE CORPORATION /s/ Robert S. Chilton ------------------------- Robert S. Chilton Chief Financial Officer EXHIBIT INDEX Exhibit Number Description -------------- ----------------------------------------------- 99.1 Press Release issued by HemaCare, dated August 13, 2004 99.2 Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, at a conference call conducted by HemaCare Corporation on August 13, 2004